BamSEC and AlphaSense Join Forces
Learn More

Kyverna Therapeutics Inc. – Material Contracts

NASDAQ: KYTX    
Share price (6/2/26): $7.90    
Market cap (6/2/26): $480 million

Material Contracts Filter

EX-10.2
from 8-K 9 pages May 14, 2026 Marc Grasso, M.D. via Email to [...***...] Dear Marc
12/34/56
EX-10.1
from 8-K 19 pages April 30, 2026 Gregory Martini via Email to […***…] Re: Employment Terms Dear Gregory: Kyverna Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on May 18, 2026 (The “Start Date”); Provided, However, if Your Employment Does Not Commence on the Start Date, This Letter Shall Be Null and Void and Without Force or Effect. Position
12/34/56
EX-10.1
from 10-Q 19 pages January 13, 2026 Mayo Pujols via Email to […***…] Re: Employment Terms Dear Mayo: Kyverna Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on February 9, 2026 (The “Start Date”); Provided, However, if Your Employment Does Not Commence on the Start Date, This Letter Shall Be Null and Void and Without Force or Effect. Position
12/34/56
EX-10.7
from S-8 7 pages Kyverna Therapeutics, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.6
from S-8 9 pages Kyverna Therapeutics, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.1
from 8-K 16 pages Kyverna Therapeutics, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 7 pages January 9, 2026 Christi Shaw via Email to [...***...] Re: Employment Terms Dear Christi: Kyverna Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on January 12, 2026 (The “Start Date”); Provided, However, if Your Employment Does Not Commence on the Start Date, This Letter Shall Be Null and Void and Without Force or Effect. Position
12/34/56
EX-10.2
from 8-K 9 pages 1. Advisory Services. Commencing as of June 30, 2025 (The “Advisor Date”), the Company Will Continue Your Full-Time Employment as a Strategic Advisor to Marc Grasso, M.D. Through August 8, 2025 (The “Advisor Period”). During the Advisor Period, You Shall Provide Such Assistance to Dr. Grasso as He May Reasonably Request From Time to Time, Primarily Relating to the Transition and Transfer of Your Prior Services. as Compensation for Your Services During the Advisor Period, the Company Shall Continue to Provide You With Your Current Salary ($375,000 Annually), You Will Continue to Vest in Your Outstanding Equity Compensation, and You Will Remain Eligible for Benefits on the Same Basis as Any Other Full-Time Employee. for the Avoidance of Doubt, During the Advisor Period Your Employment Continues to Be “At Will” and May Be Terminated by Either You or the Company at Any Time and for Any Reason. Notwithstanding the Duration of the Advisor Period Specified Above, the Advisor Period May Be Extended by Mutual Written Agreement of You and the Company. You Agree That, Effective as of the Advisor Date, You Have Resigned From (A) All Positions That You Held With the Company or Any of Its Subsidiaries and Affiliates, Including, Without Limitation, Officer, Manager or Director, but Excluding Your Continued Services as an Employee Pursuant to the Terms of This Agreement, and (B) All Fiduciary Positions (Including as a Trustee) You Held With Respect to Any Employee Benefit Plans or Trusts Established by the Company or Any Affiliate. You Agree to Execute Any Additional Documents Consistent With the Foregoing Resignations That the Company May Reasonably Request
12/34/56
EX-10.1
from 8-K 16 pages June 5, 2025 Marc Grasso, M.D. via Email Re: Employment Terms Position Compensation and Benefits
12/34/56
EX-10.16
from 10-K 6 pages Kyverna Therapeutics, Inc. Restated Non-Employee Director Compensation Program Effective March 25, 2025
12/34/56
EX-10.8
from 10-K 19 pages December 30, 2024 Naji Gehchan via Email Re: Employment Terms Dear Naji: Kyverna Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on January 22, 2025 (The “Start Date”). Position
12/34/56
EX-10.3
from S-8 7 pages Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.2
from S-8 9 pages Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.1
from 8-K 7 pages November 8, 2024 in Person and via Email Dr. James Chung Dear James: This Letter (The “Agreement”) Sets Forth the Terms and Conditions of Your Separation From Kyverna Therapeutics, Inc. (The “Company”) in Connection With Your Termination of Employment. 1
12/34/56
EX-10.3
from 8-K 14 pages Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 9 pages 1. Separation. as a Result of Your Voluntary Resignation, Your Last Day of Work With the Company and Your Employment Termination Date Was September 13, 2024 (The “Separation Date”). You Agree That, Effective as of the Separation Date, You Have Resigned From (A) All Positions That You Held With the Company or Any of Its Subsidiaries and Affiliates, Including, Without Limitation, as an Employee, Officer, Manager or Director and (B) All Fiduciary Positions (Including as a Trustee) You Held With Respect to Any Employee Benefit Plans or Trusts Established by the Company or Any Affiliate, and You Hereby Confirm That Your Resignation Was Not Due to Any Disagreement With the Company Relating to Any of the Company’s Operations, Policies or Practices. You Agree to Execute Any Additional Documents Consistent With the Foregoing Resignations That the Company May Reasonably Request
12/34/56
EX-10.1
from 8-K 16 pages September 14, 2024 Warner Biddle via Email Re: Employment Terms Position
12/34/56
EX-10.5
from S-8 12 pages Kyverna Therapeutics, Inc. 2024 Employee Stock Purchase Plan Adopted by the Board of Directors: January 24, 2024 Approved by the Stockholders: January 30, 2024 Ipo Date: February 7, 2024
12/34/56
EX-10.2
from S-8 22 pages Kyverna Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: January 24, 2024 Approved by the Stockholders: January 30, 2024 Ipo Date: February 7, 2024
12/34/56
EX-10.4
from S-1/A 4 pages Kyverna Therapeutics, Inc. Rsu Award Grant Notice
12/34/56